Free Trial

KalVista Pharmaceuticals (KALV) 10K Form and Latest SEC Filings 2026

KalVista Pharmaceuticals logo
$26.71 +0.05 (+0.19%)
Closing price 04:00 PM Eastern
Extended Trading
$26.66 -0.05 (-0.18%)
As of 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest KalVista Pharmaceuticals SEC Filings & Recent Activity

KalVista Pharmaceuticals (NASDAQ:KALV) has submitted 457+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in KalVista Pharmaceuticals's financial statements. The most recent filing was a Form SC TO-C submitted on May 5, 2026.

Form 4
KalVista Pharmaceuticals, Inc. Reports Ownership Change on Apr. 20, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
KalVista Pharmaceuticals Files Current Report on Apr. 29, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
KalVista Pharmaceuticals Files Quarterly Report on Nov. 10, 2025

The 10-Q contains KalVista Pharmaceuticals's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

KalVista Pharmaceuticals SEC Filing History

Browse KalVista Pharmaceuticals' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/05/2026 3:51 PM
Chiesi Farmaceutici SpA (1464415) Filed by
KalVista Pharmaceuticals (1348911) Subject
Form SC TO-C
05/01/2026 4:32 PM
KalVista Pharmaceuticals (1348911) Subject
MILLENNIUM MANAGEMENT LLC (1273087) Filed by
Form SCHEDULE 13G/A
04/30/2026 3:35 PM
KalVista Pharmaceuticals (1348911) Filer
Form 10-KT/A
04/29/2026 7:30 AM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/20/2026 6:40 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 6:40 PM
KalVista Pharmaceuticals (1348911) Issuer
Piekos Brian (1815308) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 6:41 PM
KalVista Pharmaceuticals (1348911) Issuer
Sweeny Nicole (1827505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 6:42 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2026 4:50 PM
KalVista Pharmaceuticals (1348911) Issuer
Koh Bong Y (1615979) Reporting
Shah Nimish P (1698082) Reporting
Venrock Healthcare Capital Partners EG, L.P. (1808512) Reporting
Venrock Healthcare Capital Partners III, L.P. (1738048) Reporting
VHCP Co-Investment Holdings III, LLC (1750761) Reporting
VHCP Management EG, LLC (1808518) Reporting
VHCP Management III, LLC (1738053) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/25/2026 3:35 PM
KalVista Pharmaceuticals (1348911) Filer
Form 10-KT
03/25/2026 6:16 AM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/10/2026 5:47 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 6:44 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 6:42 PM
KalVista Pharmaceuticals (1348911) Issuer
Piekos Brian (1815308) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 6:42 PM
KalVista Pharmaceuticals (1348911) Issuer
Sweeny Nicole (1827505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 6:43 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 6:44 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 6:44 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 6:44 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 6:45 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/26/2026 4:00 PM
KalVista Pharmaceuticals (1348911) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
01/21/2026 3:09 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:10 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:10 PM
KalVista Pharmaceuticals (1348911) Issuer
Piekos Brian (1815308) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:11 PM
KalVista Pharmaceuticals (1348911) Issuer
Sweeny Nicole (1827505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:11 PM
Arif Bilal (1959750) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2026 5:03 PM
KalVista Pharmaceuticals (1348911) Subject
Point72 Asset Management, L.P. (1603466) Filed by
Form SCHEDULE 13G/A
01/12/2026 5:34 PM
KalVista Pharmaceuticals (1348911) Subject
Point72 Asset Management, L.P. (1603466) Filed by
Form SCHEDULE 13G
01/08/2026 3:47 PM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/30/2025 3:28 PM
KalVista Pharmaceuticals (1348911) Subject
MILLENNIUM MANAGEMENT LLC (1273087) Filed by
Form SCHEDULE 13G/A
12/09/2025 5:16 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/04/2025 3:02 PM
KalVista Pharmaceuticals (1348911) Issuer
Sweeny Nicole (1827505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/26/2025 5:49 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/26/2025 5:50 PM
KalVista Pharmaceuticals (1348911) Issuer
Piekos Brian (1815308) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/26/2025 5:46 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/26/2025 5:47 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/21/2025 3:07 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:11 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:11 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:13 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/10/2025 3:45 PM
KalVista Pharmaceuticals (1348911) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/04/2025 4:21 PM
Frazier Life Sciences Public Fund, L.P. (1863769) Filed by
KalVista Pharmaceuticals (1348911) Subject
Form SCHEDULE 13D/A
10/08/2025 5:58 PM
Arif Bilal (1959750) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 3
Initial statement of beneficial ownership of securities  
10/08/2025 5:59 PM
Arif Bilal (1959750) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/06/2025 6:15 AM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/02/2025 5:27 PM
KalVista Pharmaceuticals (1348911) Issuer
Sensenig Bethany (1899935) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/02/2025 5:28 PM
KalVista Pharmaceuticals (1348911) Issuer
Sensenig Bethany (1899935) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2025 5:28 PM
KalVista Pharmaceuticals (1348911) Issuer
Unkart Edward W (1306267) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2025 5:29 PM
Fairey William (1727275) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2025 5:30 PM
KalVista Pharmaceuticals (1348911) Issuer
Treanor Patrick (1929863) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2025 5:30 PM
KalVista Pharmaceuticals (1348911) Issuer
Stuart Nancy (1594774) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2025 5:31 PM
KalVista Pharmaceuticals (1348911) Issuer
Pereira Brian JG (1298146) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2025 6:15 AM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/29/2025 3:27 PM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/11/2025 6:45 AM
KalVista Pharmaceuticals (1348911) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
09/11/2025 6:24 AM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/09/2025 6:02 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/26/2025 6:59 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/26/2025 7:00 PM
KalVista Pharmaceuticals (1348911) Issuer
Sweeny Nicole (1827505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/26/2025 6:57 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/25/2025 8:33 PM
KalVista Pharmaceuticals (1348911) Issuer
Sweeny Nicole (1827505) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/25/2025 8:33 PM
KalVista Pharmaceuticals (1348911) Issuer
Sweeny Nicole (1827505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/25/2025 6:45 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/25/2025 6:46 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/25/2025 6:46 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/21/2025 4:00 PM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/21/2025 3:35 PM
KalVista Pharmaceuticals (1348911) Filer
Form DEF 14A
08/21/2025 3:37 PM
KalVista Pharmaceuticals (1348911) Filer
Form DEFA14A
08/21/2025 3:39 PM
KalVista Pharmaceuticals (1348911) Filer
Form ARS
08/20/2025 4:20 PM
Frazier Life Sciences Public Fund, L.P. (1863769) Filed by
KalVista Pharmaceuticals (1348911) Subject
Form SCHEDULE 13D/A
08/19/2025 3:26 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025 3:27 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2025 4:29 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2025 7:50 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2025 7:56 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2025 3:27 PM
KalVista Pharmaceuticals (1348911) Filer
Form 424B5
07/10/2025 6:13 AM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/07/2025 7:39 AM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/20/2025 6:27 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2025 6:28 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2025 6:28 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2025 10:44 AM
Capital World Investors (1422849) Filed by
KalVista Pharmaceuticals (1348911) Subject
Form SCHEDULE 13G/A
(Data available from 1/1/2016 forward)

KalVista Pharmaceuticals SEC Filings - Frequently Asked Questions

KalVista Pharmaceuticals (KALV) has submitted 457+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

KalVista Pharmaceuticals's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on KalVista Pharmaceuticals's financial statements page.

The most recent filing was a Form SC TO-C submitted on May 5, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:KALV) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners